Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short term prognosis in breast cancer

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 3091-3097

  Eissa, Sanaa ^a   Khalifa, A ^a   El Gharib, Amina ^a   Salah, Nevien ^a   Mohamed, Mostafa K ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Breast cancer; Epidermal growth factor receptors; Flow cytometry; HER 2 neu; Oncogenes; Prognostic factor; Tumor suppressor genes

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MUTANT PROTEIN; ONCOPROTEIN; PROGESTERONE RECEPTOR; PROTEIN P53; STEROID RECEPTOR;

ADULT; BREAST CANCER; BREAST CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; MOLECULAR GENETICS; MULTIVARIATE ANALYSIS; ONCOGENE C ERB; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; DNA, NEOPLASM; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLOIDIES; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 0030865747     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (71)

1. Muir C, Waterhouse J, Mack T: Cancer incidence in five continents. International Agency for Research on Cancer. Lyon 3: 1987.
2. El-Bolkainy M: General pathology of cancer. In: General pathology of cancer (El-Balkainy, ed). Cairo, Al-Sadekaa Graphics Center (AGC), 1991.
3. Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D, Levin W, Stualt S, Udove J, Ullrich A, Press M: Studies of the Her-2/neu protooncogene in human breast ovarian cancer. Science 244: 707-712, 1989.
4. Contesso G, Omar S, Ibrahim A et al: Prospective inter-comparative study of breast cancer between Egypt and France. Egypt J Oncol 2: 55-63, 1982.
5. El-Ghazawy IH: A comparative prospective clinicopathological study of breast cancer in Egyptian and French females. Ph D thesis, Ain Shams Faculty of Medicine, Cairo, Egypt, 1987.
6. Richards M, Coleman R, Hamza K et al: Advanced breast cancer in Egyptian women clinical features and response to endocrine therapy. The Anglo-Egyptian health agreement collaborative study. Eur J Surg Oncol 18: 219-223, 1992.
7. 0) breast carcinoma. J Clin Oncol 7: 355-366, 1989.
8. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed 15 years. Br J Cancer 11: 359-377, 1957.
9. Peltschuk L, Kim DS, Nayer K, Feldman JG, Eisenberg KB, Carter AC, Rong ZT, Thelmo WL, Fleisher J, Greene GL: Immunocytochemical estrogen and progestin receptor assays in breast cancer with monoclonal antibodies. Histopathologic, demographic, and biochemical correlations and relationship to endocrine response and survival. Cancer (Phila) 66: 1663-1670, 1990.
10. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 320: 627-633, 1989.
11. Meyer JS: Cell kinetics in selection and stratification of patients for adjuvant therapy of breast carcinoma. Natl Cancer Inst Monogr 1: 25-28, 1986.
12. Spyratos F, Maudelonde T, Brouillet JA et al: Cathepsin D; an independent prognostic factor for metastasis of breast cancer. Lancet 2: 1115-1118, 1989.
13. Tholpe SM, Rochefolt J, Garcia M et al: Association between high concentrations of M 52,000 cathepsin D and poor prognosis in primary human breast cancer. C'ancer Res 49: 6008-6014, 1989.
14. Tandon AK, Clark GM, Chamness GC, Chirgwin JM, McGuire WL: Cathepsin D and prognosis in breast cancer. N Engl J Med 322: 297-302, 1990.
15. Sainsbuly JRC, Farndon JR, Needham GK, Malcolm AJ and Harris AL: Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 2: 1398-1402, 1987.
16. Schecter AL, Stem DF, Vaidyanathan L, Decker SJ: The neu oncogene: an erbB-related gene encoding a 185.000 Mr tumor antigen. Nature 572: 513-516, 1984.
17. Maguire HC Jr, Greene MI: The neu(c-erbB-2) oncogene. Semin Oncol 16: 148-55, 1989.
18. Clark GM, McGuire WL: Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 57: 944-948, 1991.
19. Berns EMJ, Klijn JGM, Van Putten WLF, van Staveren IL, Portengen H, Foekens JA.: c-myc Amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52: 1107-1113, 1992.
20. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 255: 177-182, 1987.
21. Ro J, El-Naggar A, Ro JY, Blick M, Flye D, Fraschini G, Fritsche H, Holtobagyi G: c-erbB-2 amplification in node-negative human breast cancer. Cancer Res 49: 6941-6944, 1989.
22. Tsuda H, Hirohashi S, Shimosato Y, Hirato T, Tsugane S, Yamamoto H et al: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene complification units: hst-1 / int-2 and c-erbB-2/ ear-1. Cancer Res 49: 3104-3108, 1989.
23. Ali IU, Campbell G, Lidereau R, Callahan R.: Amplification of cerbB-2 and aggressive human breast tumors. Science 240: 1795-1796, 1988.
24. Heintz NH, Leslie KO, Rogers LA, Howard PL: Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1114: 160-163, 1990.
25. Iglehart JD, Kraus MH, Langton BC, Huper G, Kens BJ, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701-6707, 1990.
26. Tandon AK, Clark GM, Chammess GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer. Clin Oncol 7: 1120-1128, 1989.
27. Venter D J, Kumar S, Tuzi N L, Gullick W J.: Over-expression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 11: 69-72, 1987.
28. May E, Mouriesse H, May-Levin F, Qian J F, May P, Delarur JC: Human breast cancer: identification of populations with a high risk of early relapse in relation to both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer 62: 430-435, 1990.
29. Allred DC, Clark GM, Tandon AK, Molina R, Tolmey DC, Osbome CK et al: HER-2/ neu in node-negative breast cancer: prognostic significance of over-expression influenced by the presence of in situ carcinoma. J Clin Oncol 10: 599-605, 1992.
30. Thor AD, Schwaltz LH, Koemer FC, Edgerton SM, Skates SJ, Yin S, et al: Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res 49: 7147-7152, 1989.
31. Bames DM, Lammie GA, Milis RR, Gullick WL, Allen DS, Altman DG: An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer 58: 448-452, 1988.
32. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R et al: Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44-49, 1991.
33. Kallioniemi OP, Holli K, Visakolpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer . Int J Cancer 49: 650-655, 1991.
34. Battifora H, Gaffey M, Estaban J, Mehta P, Bailey A, Faucett C et al: Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Modern Pathol 4: 466-474, 1991.
35. Winstanley J, Cooke T, Murray G, Platt-Hjggins A, George W, Holts S, Myskov M, Spedding A, Barrraclough B, Rudland P: The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 63: 447-450, 1991.
36. Gusterson BA, Gelbel RD, Goldhirsch A, Price KN, Save-Sode-borgh J, Anbazhagan R et al: Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 10: 1049-1056, 1992.
37. Gullick W, Love S, Wright C, Bames D, Gusterson B, Harris A, Altman D: c-erb B-2 protein overexpression in breast cancer is a risk factor in patients with involved lymph nodes. Br J Cancer 63: 434-438, 1991.
38. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up. J Clin Oncol 10: 1044-1048, 1992.
39. Wright C, Angus B, Nicholson S, Sainsbuly JR, Cairns J, Gullick WD et al: Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 49: 2087-2090, 1989.
40. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O et al: Neu protein over-expression in breast cancer. N Engl J Med 319: 1239-1245, 1988.
41. Ravdin PM, Chamness GC: The c-erbB-2 protooncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers. areview. Gene 159(1): 19-27, 1995.
42. Baltek J, Baltkova J, Vojtesek B, Staskova z, Rejthar A, Kovarik J, Lane D P: Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 46: 839-844, 1990a.
43. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D: p53 expression in breast cancer. Int J Cancer 41: 178-183, 1988a.
44. Davidoff A M, Herndon JE, Glover NS, Kerns BJM, Pence JC, Iglehart JD, Marks JR: Relation between p53 over-expression and established prognostic factors in breast cancer. Surgely 110: 259-264, 1991a.
45. Horak E, Smith K, Bromley L, Lejeune S, Greenall M, Lane D, Hallis AL: Mutant p53, EGF receptor and c-erbB-2 expression in human breast cancer. Oncogene 6: 2277-2284, 1991.
46. Ostrowski JL, Sawan A, Henry L, Wlight C, Hemy JA, Hennessy C, Lennard TJW, Angus B, Home CHW: p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 164: 75-81, 1991.
47. Walker RA, Dearing SJ, Lane DP, Varley JM: Expression of p53 protein in infiltrating and in-situ breast carcinomas. J Pathol 165: 203-211, 1991.
48. Eissa S, El-Sharkawy T: Correlation of c-erbB-2 oncogene expression: DNA cell cycle kinetics in colorectal carcinoma. Egypt J Biochem 11: 273-276, 1993.
49. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 7: 248-254, 1976.
50. Cox DR, Oakes D: Analysis of sulvival data. New York: Chapman-Hall, 1984.
51. Kaplan El, Meier P: Nonparametric estimation from incomplete observations. Am Stat Assoc 55: 457, 1958.
52. Abbott Laboratories Diagnostic Division. Abbott ER-EIA Monoclonal package inselt, 1984.
53. Abbott Laboratories Diagnostic Division. Abbott PR -EIA Monoclonal package insert, 1984.
54. Nicholson S, Sainsbuly JRC, Needham GK, Chambers P, Farndon J R, Hanis AL: Quantitative assays of EGFR in human breast cancer: cut off points of clinical relevance. Int J Cancer 42: 36-41, 1988.
55. Ravdin PM, Weidner N, Dressler L: Breast cancer prognostic factors-the search goes On. J Natl Cancer Inst 869(7): 480-483, 1994.
56. Weidner N, Folkman J, Pozza F et al: Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84: 1875-1887, 1992.
57. Gasparini G, Gullick WJ, Bevilacqua P et al: Human breast cancer: prognostic significane of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. J Clin Oncol 10: 686-695, 1992.
58. Noguchi M, Koyasaki N, Kitagawa H, Earashi M, Thomas M et al: Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B2 expression in patients with breast cancer. Arch Surg 128: 242-246, 1993.
59. Foekens JA, Peters HA, Poltengen H et al: Cell biological prognostic factors in breast cancer . A review. J Clin Immunoassay 14: 184-195, 1991.
60. McGuire WL, Tandon AK, Allred D, Chamness GC, Clark GM: Breast cancer update: Prognostic plofile markers. Division of speciality lab. INC. How to use prognostic factors in ANN breast cancer patients. J Natl Cancer Inst 82: 1451-1453, 1992.
61. Horwitz KB, Wei LL, Sedlacek SM, D'alville CN: Progestin action and progesterone receptor structure in human breast cancer: a review. Recent Prog. Holm. Res 41: 249-316, 1988.
62. Hedley DW, Clark GM, Comelisse CJ, Killander D, Kute T, Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482-485, 1993.
63. Klijin JGM, Berns MJJ, Schmitz PIM, Fokens JA: The clinical significance of epidelmal growth receptor in human breast cancer. A review of 5232 patients. Endocrine Rev 13: 3-17, 1992.
64. Nigochi M, Mizukami Y, Kinoshita K, Earashi M, Thomas M, Miyazai I: The prognostic Significance of epidermal growth factor receptor expression in breast cancer. Jpn J Surg 24: 889-894, 1994.
65. O' Reilly S, Bames D, Campiejohn R, Baltkova J, Gregory W, Richards M: The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 6: 444-446, 1991.
66. Patterson M, Dietrich K, Danyluk J, Paterson A, Lees A, Jamil N, Hanson J, Jenkins H, Krause B, McBlain W, Slarnon D, Fourney R: Correlation between c-erbB-2 amplification and risk recurrent disease in node-negative breast cancer. Cancer Res 51: 556-567, 1991.
67. Schimmelpenning H, Eriksson ET, Falkmer UG, Rutqvist LE, Johansson H, Anders Fallenius, Auer GU: Prognostic significance of immuno-histochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer. Eur J of Surg Oncol 18: 530-537, 1992.
68. Elledge RM, Fuqua SAW, Clark GM, Pujol P, Allred C: The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Treatment 27: 95-102, 1993.
69. Isola J, Visakolpi T, Holli K, Kallioniemi OP: Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer • patients. J Natl Cancer Inst 84: 1109-1114, 1992.
70. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, Mukai K, Hirohashi S: Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 82: 835-840, 1991.
71. De Polter CR, Schelfhout AM: The neu-protein and breast cancer. Virchows Arch 426(2): 107-115, 1995.